The key publication from this collaboration has been published in the Lancet on 4 October 2018. Please click on the subsequent links to obtain full-text and a slide deck.
- Lipoprotein(a) [Lp(a)] is a lipoprotein composed of apolipoprotein(a) covalently bound to apolipoprotein B of a low-density lipoprotein-like particle.
- Lp(a) is an established risk factor for cardiovascular disease. Lp(a) has pro-inflammatory and pro-thrombotic properties and may thereby promote the developement of atherosclerosis.
- In contrast to other major lipoproteins, there is currently no approved specific therapy available to lower circulating plasma levels of Lp(a).
Lipoprotein(a) Studies Collaboration (LPASC) has harmonised Lp(a) data from prospective cohort studies and clinical trials. The overarching aim of the consortium is to:
- better understand the role of Lp(a) as a independent risk marker in the primary vs. secondary prevention setting,
- characterise the effects of different medications on Lp(a) concentration, and
- evaluate the usefulness of Lp(a) measurements in risk prediction models over and beyond information on conventional risk factors.
[table “” not found /]